A research team at Massachusetts Institute of Technology (MIT) developed a capsule about the size of a blueberry that holds a tiny needle that, after being swallowed, injects insulin into the stomach.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Eli Lilly embraced a U.S. government proposal to end a decades-old system of rebates drugmakers make to industry middlemen.
Novo Nordisk reported solid growth for the company’s new diabetes drug and will submit a tablet version – a key growth hope – for U.S. approval in first-quarter 2019, lifting the Danish drugmaker’s shares.
Two powerful U.S. lawmakers sent letters to the three leading insulin manufacturers requesting information on why its cost has skyrocketed in recent years and how much the companies profit from the life-sustaining diabetes treatment.
The cost of insulin for treating type 1 diabetes in the United States nearly doubled over a five-year period, underscoring a national outcry over rising drug prices, according to a new analysis shared with Reuters.
An advisory panel to the U.S. Food and Drug Administration was divided over whether to recommend approval of a treatment for type 1 diabetes developed by Lexicon Pharmaceuticals Inc. and France’s Sanofi SA.
The House Committee on Oversight and Reform launched an investigation into prescription drug pricing practices.
Diabetic patients who take statins to treat high cholesterol may get an added benefit: a lower risk of damage to the retina, a new study suggests.
For a while now there has been a heated debate surrounding hybrid and closed loop insulin systems.
The cost of insulin prevents many people with diabetes from taking it as directed, a small survey suggests.